Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Munster – page 58

701 clinical trials in Munster, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Munster at a glance
701
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

701 trials in Munster

Open in trial search

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Waldenstrom's macroglobulinaemia

Not recruiting

Study on the Effectiveness of Bortezomib, Rituximab, and Ibrutinib for Patients with Newly Diagnosed Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Acute myeloid leukaemia

Not recruiting

Study on Venetoclax, Cytarabine, and Mitoxantrone for Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Technische Universitat Dresden

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Not recruiting

Study on Brigatinib, Ceritinib, and Alectinib for Patients with Advanced ALK+ Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Myopia

Not recruiting

Study on Low-Dose Atropine Sulfate Eye Drops for Controlling Progressive Myopia in Caucasian Children

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Atropine Sulfate
  • Sponsor:Medical Center - University Of Freiburg

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Major depression

Not recruiting

Study on the Effects of Mebufotenin (GH001) for Patients with Treatment-Resistant Depression

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Mebufotenin
  • Sponsor:GH Research Ireland Limited

Acute myeloid leukaemia

Not recruiting

Study of Pembrolizumab and Azacitidine for Patients with Acute Myeloid Leukemia Facing Imminent Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Munster

What the registry says about research in the country

01 Oncology & Hematology

Advanced research focusing on lymphoma treatments and innovative therapies for breast cancer and lung cancer. Studies include evaluations of new combinations of targeted therapies and immunotherapy approaches.

  • Diffuse Large B-Cell Lymphoma
  • Advanced Breast Cancer
  • Non-Small Cell Lung Cancer
  • Acute Myeloid Leukemia

Several trials are exploring novel treatment combinations and maintenance therapies for various blood cancers.

02 Metabolic & Cardiovascular Disorders

Comprehensive studies addressing obesity management and cardiovascular disease prevention. Research includes innovative approaches for weight management and heart failure risk reduction.

  • Obesity Treatment
  • Type 2 Diabetes
  • Heart Failure Prevention
  • Cardiovascular Risk Management

Multiple trials are investigating new therapeutic options for weight management and cardiovascular health improvement.

03 Dermatology & Immunology

Innovative research in treating chronic skin conditions including plaque psoriasis and hidradenitis suppurativa. Studies focus on novel biological therapies and targeted treatments.

  • Moderate to Severe Plaque Psoriasis
  • Hidradenitis Suppurativa
  • Chronic Rhinosinusitis

Trials are evaluating next-generation treatments for inflammatory skin conditions and immune-mediated disorders.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.